{"prompt": "['9.2.2.3', 'Initial characteristics', '49', '9.2.2.4', 'Analysis of the main judgement criterion', '49', '9.2.2.5', 'Analysis of the secondary judgement criteria', '49', '9.2.2.6', 'Handling of missing values/censoring/discontinuations', '50', '10 Quality assurance', '51', '11', 'Ethical and regulatory aspects', '51', '11.1 Qualification of the research and patient information', '52', '11.1.1', 'Information sheet', '52', '11.1.2', 'Enlightened consent', '52', '11.2', 'Benefit / risk ratio', '52', '11.3', 'Confidentiality of the data', '53', '11.4', 'Confidentiality and Good Clinical Practices', '53', '11.5', 'Submitting the protocol to the CPP and ANSM', '53', '11.6', 'Amendments to the protocol', '53', '11.7', 'Computerization of the data', '54', '11.8', 'Curriculum vitae and signature of the protocol', '54', '11.9', 'Insurance', '54', '11.10', 'Study report and publications', '54', '12', 'Organization of the study', '55', '12.1', 'Scientific committee', '55', '12.2', 'Independent monitoring and safety committee for the study', '55', '13', 'Medium and long term perspectives', '55', '14 References', '57', '15 Appendices', '61', '15.1', 'Appendix 1: Nosebleed monitoring sheet', '61', '15.2', 'Appendix 2: ESS questionnaire', '62', '15.3', 'Appendix 3: ENT monitoring examination', '63', '15.4', 'Appendix 4: Epistaxis emergency', '64', 'Page 6 of 64']['LIST OF ABBREVIATIONS', 'ALK', 'Activin-like-receptor-type 1', 'ANSM', 'Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9', '(French National Agency for Drug Safety)', 'AVF', 'Arteriovenous Fistula', 'BMP', 'Body Morphogenetic Proteins', 'BMPR2', 'Body Morphogenetic Protein Receptor, type Il', 'CHU', 'Centre Hospitalier Universitaire (University Teaching Hospital)', 'CNIL', 'French Commission for Data Protection and Liberties', 'CNV', 'Corneal NeoVascularization', 'CPP', 'Comit\u00e9s de Protection des Personnes (French Ethics Committee)', 'CRF', \"Case Report Form (Cahier d'observation)\", 'DSMB', 'Data and Safety Monitoring Board', 'EC', 'Endothelial Cells', 'ENG', 'Endogline', 'ENT', 'Ear, Nose and Throat Specialist', 'ESS', 'Epistaxis Severity Score', 'FKBP', 'FK-Binding Protein', 'Flt-1', 'Fms-like tyrosine kinase', 'HAS', 'Haute Autorit\u00e9 de Sant\u00e9 (French National Authority for Health)', 'HHT', 'Hereditary Hemorrhagic Telangiectasia', 'IMER', 'Information M\u00e9dicale Evaluation Recherche', '(Medical Information Research Assessment)', 'IV', 'Intra venous', 'IWRS', 'Interactive Web Response System', 'KO', 'Knock Out', 'MAPK', 'Mitogen-activated protein kinases', 'MCP', 'Monocyte Chemoattractant Protein', 'mRNA', 'messenger Ribonucleic Acid', 'OLP', 'Oral Lichen Planus', 'PAH', 'Pulmonary Arterial Hypertension', 'PNDS', 'Protocoles Nationaux de Diagnostic et de Soins', '(French National Protocol for Diagnosis and Healthcare)', 'SAE', 'Serious Adverse Events', 'SAS', 'Statistical Analysis System', 'SMAD', 'Mothers Against Dpp homologue 4', 'SPC', 'Summary of Product Characteristics', 'TGF-\u00df', 'Transforming Growth Factor-\u00df', 'TNF', 'Tumor Necrosis Factor', 'VEGF', 'Vascular Endothelial Growth Factor', 'VEGFR', 'Vascular Endothelial Growth Factor Receptor.', 'Page 7 of 64']['LIST OF FIGURES', 'Figure 1: Angiogenesis results from an activation phase and a maturation phase. (Taken', 'from David L. 28)', '16', 'Figure 2: Involvement of the BMP9/ALK1/endoglin pathway in HHT (taken from S. Bailly31 17', 'Figure 3: Angiogenic balance in HHT (taken from S. Bailly31', '17', 'Figure 4 General diagram of the study', '24', 'Figure 5: Inclusions flow chart', '27', 'Figure 6: Schedule', '29', 'Figure 7: Diagram of the running of the study', '30', 'Figure 8: Diagram of the running of the study', '37', 'LIST OF TABLES', 'Table 1: Synopsis of the study per patient', '42', 'Page 8 of 64']\n\n###\n\n", "completion": "END"}